Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: A review

Median percent change in TG and LDL-C in Omacor/Lovaza studies pooled by baseline TG inclusion criteria (From CDER-FDA Statistical Review¹⁰). CDER, Center for Drug Evaluation and Research; C.I., confidence interval; FDA, Food and Drug Administration; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride. (To convert TG to mmol/L, multiply by 0.0113.)

Comparison of percent changes in mean values from baseline to end point for EPA or DHA treatment. Percent changes in mean TG or LDL-C, adjusted by placebo or control group values for DHA (filled circles) and EPA (open squares), and corresponding 95% CI (dashed lines) are presented. ^aThe 95% CI was not included where large data dispersion at end point precluded reasonable estimation. ∗N represents the total number of crossover study participants. Egert et al²¹ and Tanaka et al³⁰ reported median values. BL, baseline; CNTRL, control; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; Exp, experimental group; LDL-C, low-density lipoprotein cholesterol; PBO, placebo; TG, triglyceride. (To convert LDL-C to mmol/L, multiply by 0.0259; to convert TG to mmol/L, multiply by 0.0113.)